Bristol Myers Squibb (BMS) is to acquire 2seventy bio, its partner in developing multiple myeloma drug Abecma, for about $286m. The deal follows a turbulent three years for 2seventy bio, which recorded net losses of $217.57m in 2023 and saw 54% of its workforce cut in a restructuring and refocusing drive. The acquisition is expected to close in Q2 2025.
M&S issues update as crippling nationwide IT outage still ongoing – The Sun
Marks & Spencer (M&S) halted online orders in the UK and Ireland following a cyber attack, leading to a 5% drop in share price. Physical
